Ads
related to: merck & co
Search results
Check Out What Whales Are Doing With MRK - Merck & Co (NYSE:MRK)
Benzinga· 12 hours agoLoading... Loading... Investors with a lot of money to spend have taken a bullish stance on Merck & Co MRK . And retail traders should know. We noticed ...
Why Merck & Co Inc (NYSE: MRK) Is A Stock Not To Be Discarded In 2024 – Marketing Sentinel
Marketing Sentinel· 4 days agoIn today’s recent session, 2.33 million shares of the Merck & Co Inc (NYSE:MRK) have been traded, and its beta is 0.42. Most recently the company’s share ...
The Zacks Analyst Blog Highlights Broadcom, Merck, Airbnb, ONEOK and PG&E
Zacks via Yahoo Finance· 20 hours agoEvery day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and...
MRK- A Big Pharma Name Growing Via Acquisitions, Product Launches
MoneyShow via Yahoo Finance· 2 days agoMerck & Co. (MRK) is a leading global drugmaker, producing a wide range of prescription drugs and vaccines in many therapeutic areas in the US and abroad ...
Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study
Market Watch· 4 days agoMerck & Co. has ended part of a late-stage study of a co-formulation of its blockbuster cancer drug Keytruda in certain skin-cancer patients because the ...
...Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment - ...
Benzinga· 4 days agoMonday, Merck & Co Inc MRK announced the discontinuation of the vibostolimab and pembrolizumab...
Earnings call: Merck sees organic growth despite market challenges By Investing.com
Investing.com· 2 days agoMerck & Co., Inc. (MRK) reported its first-quarter results for 2024, revealing a slight decline in...
Merck cancels trial of melanoma treatment due to immune-mediated adverse events
Clinical Trials Arena via Yahoo Finance· 3 days agoUS pharmaceutical company Merck & Co Inc (MSD) has discontinued a Phase III trial investigating a...
Merck halts phase 3 TIGIT trial after immune-mediated adverse events prompt discontinuations
FierceBiotech· 4 days agoMerck & Co. has bailed early on a phase 3 test of the anti-TIGIT antibody vibostolimab after a high...
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Zacks via Yahoo Finance· 3 days agoWith Merck’s growth largely depending on Keytruda, the recent pipeline setbacks do not bode well for...